The purpose of the study is to evaluate the effect of VX-407 on the pharmacokinetics of levonorgestrel (LNG) and ethinyl estradiol (EE), norgestimate (NGM) and EE, norethindrone (NET) and EE and drospirenone (DRSP) and EE. Also, to evaluate the safety and tolerability of co-administration of VX-407 with LNG/EE, NGM/EE, NET/EE and DRSP/EE.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Part A: Maximum Observed Plasma Concentration (Cmax) of LNG and EE in the Absence and Presence of VX-407
Timeframe: From Day 1 up to Day 7 and Day 21 up to Day 27
Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of LNG and EE in the Absence and Presence of VX-407
Timeframe: From Day 1 up to Day 7 and Day 21 up to Day 27
Part B (Optional): Cmax of Norelgestromin (NGMN) and Norgestrel (NG) (Active Metabolites of NGM) and EE in the Absence and Presence of VX-407
Timeframe: From Day 1 up to Day 9 and Day 23 up to Day 31
Part B (Optional): AUC0-inf of NGMN and NG (Active Metabolites of NGM) and EE in the Absence and Presence of VX-407
Timeframe: From Day 1 up to Day 9 and Day 23 up to Day 31
Part C (Optional): Cmax of NET and EE in the Absence and Presence of VX-407
Timeframe: From Day 1 up to Day 5 and Day 19 up to Day 23
Part C (Optional): AUC0-inf of NET and EE in the Absence and Presence of VX-407
Timeframe: From Day 1 up to Day 5 and Day 19 up to Day 23
Part D (Optional): Cmax of DRSP and EE in the Absence and Presence of VX-407
Timeframe: From Day 1 up to Day 7 and Day 21 up to Day 27
Part D (Optional): AUC0-inf of DRSP and EE in the Absence and Presence of VX-407
Timeframe: From Day 1 up to Day 7 and Day 21 up to Day 27